David Loew | Ipsen Leadership
Skip to main content
Ipsen Home Page
Press shift tab to select search category

Loading...
  • Media  arrow down
    < Back
    • Press Releases
    • Media Statements
    • Media Library
    • Our 2023 Integrated Annual Report is live!

      Featured Image
  • Investors arrow down
      < Back
    • Investors
    • Investors
    • Financial Results
    • Annual Reports and Accounts
    • Corporate News
    • Financial Calendar
    • Investor Events
    • Shareholder Information
    • Regulated Information
    • Key Contacts
  • Partnering
  • Careers arrow down
      < Back
    • Careers
    • Careers
    • Working at Ipsen
    • Culture
  • Press shift tab to select search category

    Loading...
  • English  EN     Français  FR     EN  arrow_down
    • English EN
    • Français FR
  • Global Global
    < Back
    • Global EN FR
    • Annual Report EN FR
    • Americas
    • Asia Pacific
    • Europe
    • United States
    • Brazil
    • Canada
    • Mexico
    • Australia
    • China
    • Singapore
    • South Korea
    • Japan
    • Belgium
    • Ukraine
    • UK
    • Germany
    • France
    • Nordics
    • Greece
    • Italy
    • Netherlands
    • Spain
    • Poland
    • Russia
    • Czech Republic
    • Switzerland
    • Austria
  • Home
  • Companyarrow down
      < Back
    • Company
    • Company
    • Leadership
    • History
    • Fondation Ipsen
  • Sciencearrow down
      < Back
    • Science
    • Science
    • Oncology
    • Rare Disease
    • Neuroscience
    • Products
    • R&D
    • Pipeline
    • Clinical Trials
    • Lay Summaries
  • Sustainabilityarrow down
      < Back
    • Sustainability
    • Sustainability
    • Environment
    • Patients
    • People
    • Governance
    • Our Standards
  • Patientsarrow down
      < Back
    • Patients
    • Patients
    • Together for Oncology
    • Together for Rare Disease
    • Together for Neuroscience
    • Collaborate with us
  • Stories
  1. Home
  2. Company
  3. Leadership
  4. David Loew

David Loew

Back
David Loew

David Loew

  • Chief Executive Officer
  • Follow in LinkedIn

David Loew was appointed as Chief Executive Officer of Ipsen on July 1, 2020.

David brings nearly 30 years of leadership and experience across a range of therapeutic areas, including oncology, CNS and cardio-metabolism, as well as consumer healthcare. He has worked in the U.S., European and international markets. He began his career at Coopers & Lybrand and Hewlett Packard in 1990 before joining Roche in 1992. Over the following two decades, David held a variety of positions, including Global Oncology Head, Global Chief Marketing Officer & Head of Global Product Strategy and Region Head, Eastern Europe, Middle East and Africa for the Pharma Division of Roche. He joined Sanofi in July 2013 as Senior Vice President, Commercial Operations Europe, where he was responsible for the prescription, consumer healthcare and generics business across the EU region. In 2016, David was appointed CEO of Sanofi Pasteur Vaccines.

David currently serves on the Boards of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), the European Federation of Pharmaceutical Industries and Associations (EFPIA), and G5 Santé, the federation of French pharmaceutical companies.

David earned his BA in Business Administration and MBA from the University of St. Gallen, Switzerland.

Related stories

Ipsen 2025 Annual General Meeting
17 April 2025 0 mins read

Ipsen 2025 Annual General Meeting

Strong growth and expanding pipeline in the first half of 2024 drive raised guidance
25 July 2024 1 mins read

Strong growth and expanding pipeline in the first half of 2024 drive raised guidance

Our 2023 Integrated Annual Report is live!
31 May 2024 1 mins read

Our 2023 Integrated Annual Report is live!

2024 Annual General Meeting
29 April 2024 0 mins read

2024 Annual General Meeting

Q1 2024 sales update
19 April 2024 0 mins read

Q1 2024 sales update

Ipsen delivers FY 2023 results and anticipates four launches in 2024
08 February 2024 1 mins read

Ipsen delivers FY 2023 results and anticipates four launches in 2024

FY 2023 results announcement 
08 February 2024 0 mins read

FY 2023 results announcement 

Examining the European Pharma legislation: EFPIA publishes the Dolon Report
10 November 2023 1 mins read

Examining the European Pharma legislation: EFPIA publishes the Dolon Report

Capital Markets Day 2023
03 November 2023 0 mins read

Capital Markets Day 2023

IPN price

€102.50

 €1.90 (1.89%)

  • Media
  • Investors
  • Partnering
  • Careers
  • Company
  • Sustainability
  • Patients
  • Stories
  • Annual Report
  • Contact us

Latest_Ipsen logo
LinkedIn Facebook Instagram Youtube
  • Terms and Conditions
  • Cookie Policy
  • Global Privacy Policy

© Ipsen Pharma. All rights reserved - 2025

You are now leaving the Ipsen group website. To continue, please click on Continue?

Continue